Stock Market Reviews

CRBP (Corbus Pharmaceuticals Holdings, Inc.) News

Get the latest news, insights, and market updates on CRBP (Corbus Pharmaceuticals Holdings, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Corbus Pharmaceuticals Announces Proposed Public Offering
  NORWOOD, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), an oncology and obesity company, today announced that it plans to offer and sell shares of its common stock or, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock in an underwritten registered public offering. All of the securities in the offering are to be sold by Corbus. The offering is subject to market condit
  Oct 30, 2025 - $CRBP
• Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25
  3.6 mg/kg dose generated ORR of 47.6% in HNSCC, 37.5% in cervical cancer and 55.6% in mUCCRB-701 continues to demonstrate a favorable safety and tolerability profileRegistrational studies planned to start in mid-2026Company to host an HNSCC KOL event during ESMO25 NORWOOD, Mass., Oct. 18, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company’) today announced data from its Phase 1/2 clinical study of CRB-701 (SYS6002) will be presented as a poste
  Oct 18, 2025 - $CRBP
• Corbus Pharmaceuticals to Present CRB-701 Phase 1/2 Data at ESMO 2025
  Data to be presented for 167 enrolled participants of which 122 were evaluable for efficacy Company to host HNSCC KOL event to review and discuss data NORWOOD, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical stage company focused on oncology and obesity, announced today the European Society for Medical Oncology (ESMO) Congress 2025 abstract for its Phase 1/2 clinical study has been released. Updated data will be presented as a poster durin
  Oct 14, 2025 - $CRBP
• Corbus Pharmaceuticals to Participate in the Upcoming Piper Sandler Virtual Oncology Symposium
  NORWOOD, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage oncology and obesity company, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a Fireside Chat at the Piper Sandler Virtual Oncology Symposium, to be held October 9-10, 2025. Piper Sandler clients can register for the event through their representative. Corbus Fireside ChatOctober 9, 2025, 10:00AM ETHos
  Oct 7, 2025 - $CRBP
• Is Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) In A Good Position To Invest In Growth?
  Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
  Sep 25, 2025 - $CRBP
• Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ESMO 2025
  KOL Panel to Discuss Data from Dose Optimization Clinical Trial of CRB-701NORWOOD, Mass., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage oncology and obesity company, today announced that it will host an in-person and virtual KOL event at the European Society for Medical Oncology (ESMO) Congress 2025 to review and discuss dose optimization data from its Phase 1/2 clinical study of CRB-701 (SYS6002). Data from
  Sep 22, 2025 - $CRBP
• FDA Grants Fast Track Designation to Corbus Pharmaceuticals’ Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma
  Dose optimization data from the Phase 1/2 study to be presented next month at ESMO 2025Second Fast Track designation granted by FDA for CRB-701 NORWOOD, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage oncology and obesity company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CRB-701 for the treatment of recurrent or metastatic head and neck squamo
  Sep 16, 2025 - $CRBP
• Corbus Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
  Phase 1/2 dose expansion data for Nectin-4 targeting ADC CRB-701 to be presented at ESMO 2025Initiated 7-day MAD portion of Phase 1 study for obesity drug CRB-913All three clinical programs (CRB-701, CRB-913, CRB-601) on track for data readouts in the second half of 2025 NORWOOD, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage oncology and obesity company, today provided a corporate update and reported fi
  Aug 5, 2025 - $CRBP
• Corbus Pharmaceuticals: Q2 Earnings Snapshot
  NORWOOD, Mass. AP) — Corbus Pharmaceuticals Holdings Inc. CRBP) on Tuesday reported a loss of $17.7 million in its second quarter.
  Aug 5, 2025 - $CRBP
• Corbus Pharmaceuticals Announces Upcoming Presentation of Dose Expansion Phase 1/2 Clinical Data for its Nectin-4 Targeting ADC CRB-701 at the 2025 ESMO Annual Congress
  NORWOOD, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, announced today that an abstract on updated clinical data from its Phase 1/2 clinical study conducted in the United States and Europe of CRB-701 (SYS6002) has been accepted for presentation as a poster at the European Society for Medical Oncology (ESMO) Congress 2025, to be held October 17-21, 2025 in Berlin, Germany. The abstract, a Pha
  Jul 30, 2025 - $CRBP